Search

Objectives: To develop guidelines, informed by health‐care consumer values and preferences, for sarcopenia prevention, assessment and management for use by clinicians and researchers in Australia and New Zealand. Methods: A three‐phase Consumer Expert Delphi process was undertaken between July 2020 and August 2021. Consumer experts included adults with lived experience of sarcopenia or health‐care utilisation. Phase 1 involved a structured meeting of the Australian and New Zealand Society for Sarcopenia and Frailty Research (ANZSSFR) Sarcopenia Diagnosis and Management Task Force and consumer representatives from which the Phase 2 survey was developed. In Phase 2, consumers from Australia and New Zealand were surveyed online with opinions sought on sarcopenia outcome priorities, consultation preferences and interventions. Findings were confirmed and disseminated in Phase 3. Descriptive statistical analyses were performed. Results: Twenty‐four consumers (mean ± standard deviation age 67.5 ± 12.8 years, 18 women) participated in Phase 2. Ten (42%) identified as being interested in sarcopenia, 7 (29%) were health‐care consumers and 6 (25%) self‐reported having/believing they have sarcopenia. Consumers identified physical performance, living circumstances, morale, quality of life and social connectedness as the most important outcomes related to sarcopenia. Consumers either had no preference (46%) or preferred their doctor (40%) to diagnose sarcopenia and preferred to undergo assessments at least yearly (54%). For prevention and treatment, 46% of consumers preferred resistance exercise, 2–3 times per week (54%). Conclusions: Consumer preferences reported in this study can inform the implementation of sarcopenia guidelines into clinical practice at local, state and national levels across Australia and New Zealand. [ABSTRACT FROM AUTHOR]

Objectives: To describe the current knowledge and practice of sarcopenia diagnosis and treatment among health‐care professionals before, directly after and 6 months after a professional development event on sarcopenia. Methods: This longitudinal study included Australian and New Zealand health‐care professionals who completed questionnaires on knowledge, practice and barriers regarding sarcopenia before, directly after and 6 months after attending a professional development event on sarcopenia. Results: A total of 250 professionals participated; 84 completed the 6‐month questionnaires. Before, directly after and at 6 months, respectively, 14.7%, 93.4% and 59.5% identified sarcopenia as a disease; 2.0%, 79.6% and 38.1% correctly answered the sex‐specific cut‐offs for low handgrip strength. Respectively, 12.0% and 14.3% reported to make sarcopenia diagnoses as part of their practice before and at 6 months. Conclusions: Knowledge about sarcopenia is limited among health‐care professionals who attended a professional development event. Retention of knowledge remains a challenge to be addressed. [ABSTRACT FROM AUTHOR]